Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326298 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
A Phase 3 study of Psoriasis and Plaque Psoriasis, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 3
- Development phase
- 234
- Enrollment target
- 20
- Study locations
NCT02326298: Completed Phase 3 study of Psoriasis and Plaque Psoriasis, sponsored by UCB Biopharma S.P.R.L..
NCT02326298 is a Phase 3 study of Psoriasis and Plaque Psoriasis that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 234 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02326298, a Phase 3 study of Psoriasis and Plaque Psoriasis, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 234 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.
Primary Outcome
The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Certolizumab Pegol
Study Locations (20)
Other
- Ps0005 553 - Náchod
- Ps0005 550 - Olomouc
- Ps0005 551 - Ostrava-Poruba
- Ps0005 552 - Prague
Ontario
- Ps0005 596 - Ajax
- Ps0005 590 - Hamilton
- Ps0005 593 - Toronto
Quebec
- Ps0005 595 - Drummondville
- Ps0005 594 - Québec
California
- Ps0005 504 - San Diego
Iowa
- Ps0005 502 - West Des Moines
Louisiana
- Ps0005 500 - Baton Rouge
Massachusetts
- Ps0005 506 - Boston
Missouri
- Ps0005 505 - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2014-12-16 |
| Est. Completion | 2018-10-24 |
| Phase | Phase 3 |
What the finished NCT02326298 record still lists
NCT02326298 is an interventional study that assigns participants to a tested intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (52% lower).
The record links to 2 conditions, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02326298 names 20 study sites across 14 states, led by Other, Ontario, Quebec.
Frequently Asked Questions
What is clinical trial NCT02326298 about?
NCT02326298 is a clinical study titled "An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)". The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.
What is the current status of trial NCT02326298?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 234 participants. The study started on 2014-12-16. Estimated completion is 2018-10-24.
What conditions does trial NCT02326298 study?
This clinical trial studies the following conditions: Psoriasis, Plaque Psoriasis.
What interventions are being tested in trial NCT02326298?
The interventions under investigation include: Placebo (OTHER), Certolizumab Pegol (BIOLOGICAL).
Who is sponsoring clinical trial NCT02326298?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02326298 being conducted?
This trial has 20 study locations across California, Iowa, Louisiana, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02326298's enrollment target sits among peer trials
234 35th of 125 higher than 91 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
- NCT05720338 · 234 participants · Phase 3
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI